Standard Techniques of Bone Mass Measurement in Adults

Lewiecki, E. Michael; Miller, Paul D.; Watts, Nelson B.

doi:10.1002/9781119266594.ch32

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 For any potential clinical trial, centralized analysis of scans, as well as measures to ensure adequate quality control and training of technologists, is essential. 34 Another limitation with the use of DXA in the NF1 population is that some patients with the most severe bone-related manifestations, such as dystrophic scoliosis or tibial dysplasia, may have metal implants that make calculations of bone mineral content in that region impossible. 31 Results can be impacted by patient positioning and technologist experience DXA: 7,9,10,[14][15][16]18,26,27,29,[37][38][39][40][41][42] Trabecular…”

Section: Measures Of Bone Healthmentioning

confidence: 99%

“…In children and younger adults, BMD is reported as a Z-score, which compares the patient’s values with controls for age, sex, and ethnicity. 34 In children, particularly those with short stature, which is common in NF1, using comparisons that do not account for body size can lead to an increase in the proportion of patients incorrectly diagnosed with low BMD. 35 To address this issue, using height-adjusted Z-scores is recommended.…”

Section: Measures Of Bone Healthmentioning

confidence: 99%

See 1 more Smart Citation

Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1

Gross,

Plotkin,

Watts

et al. 2023

Clinical Trials

View full text Add to dashboard Cite

Neurofibromatosis type 1 is a genetic syndrome characterized by a wide variety of tumor and non-tumor manifestations. Bone-related issues, such as scoliosis, tibial dysplasia, and low bone mineral density, are a significant source of morbidity for this population with limited treatment options. Some of the challenges to developing such treatments include the lack of consensus regarding the optimal methods to assess bone health in neurofibromatosis type 1 and limited data regarding the natural history of these manifestations. In this review, the Functional Committee of the Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration: (1) presents the available techniques for measuring overall bone health and metabolism in persons with neurofibromatosis type 1, (2) reviews data for use of each of these measures in the neurofibromatosis type 1 population, and (3) describes the strengths and limitations for each method as they might be used in clinical trials targeting neurofibromatosis type 1 bone manifestations. The Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration supports the development of a prospective, longitudinal natural history study focusing on the bone-related manifestations and relevant biomarkers of neurofibromatosis type 1. In addition, we suggest that the neurofibromatosis type 1 research community consider adding the less burdensome measurements of bone health as exploratory endpoints in ongoing or planned clinical trials for other neurofibromatosis type 1 manifestations to expand knowledge in the field.

show abstract

Section: Measures Of Bone Healthmentioning

confidence: 99%

Section: Measures Of Bone Healthmentioning

confidence: 99%

Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1

Gross,

Plotkin,

Watts

et al. 2023

Clinical Trials

View full text Add to dashboard Cite

show abstract

An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis

Schini,

Johansson,

Harvey

et al. 2023

J Endocrinol Invest

View full text Add to dashboard Cite

FRAX®, a simple-to-use fracture risk calculator, was first released in 2008 and since then has been used increasingly worldwide. By calculating the 10-year probabilities of a major osteoporotic fracture and hip fracture, it assists clinicians when deciding whether further investigation, for example a bone mineral density measurement (BMD), and/or treatment is needed to prevent future fractures. In this review, we explore the literature around osteoporosis and how FRAX has changed its management. We present the characteristics of this tool and describe the use of thresholds (diagnostic and therapeutic). We also present arguments as to why screening with FRAX should be considered. FRAX has several limitations which are described in this review. This review coincides with the release of a version, FRAXplus, which addresses some of these limitations.

show abstract

Standard Techniques of Bone Mass Measurement in Adults

Cited by 2 publications

References 29 publications

Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1

Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1

An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis

Contact Info

Product

Resources

About